Tozorakimab reduces mucus plugging in COPD patients

An integrated analysis of the phase 3 OBERON and TITANIA clinical trials has shown that tozorakimab, a monoclonal antibody, significantly reduces segmental mucus plugging in patients with chronic obstructive pulmonary disease (COPD).

Tozorakimab works by inhibiting both the reduced and oxidized forms of interleukin-33. This dual mechanism is believed to address both inflammation and mucus dysfunction. The study utilized a segmental mucus plug score to evaluate 18 lung segments via CT imaging. Results indicated a dose-dependent reduction in these scores at week 52 for both current and former smokers.

While the mucus-plug finding is considered exploratory, it aligns with primary trial results showing that tozorakimab reduced moderate or severe COPD exacerbations—including those requiring emergency care or hospitalization—by approximately 30% compared to a placebo.